GlassScriptPhysician profile
Michael B Dulan
NPI 1376531624
$9,046.76
in general payments reported to CMS, 2019-2025
41 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370 · 2020: $915 · 2021: $1,576 · 2022: $1,436 · 2023: $1,250 · 2024: $1,111 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688 · Education: $61.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.58 |
| Education | $61.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,942.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $960.42 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $848.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.61 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $593.06 | 2021-2025 | |
| Novo Nordisk INC | $529.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $519.06 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $383.10 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $304.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $258.24 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Currax Pharmaceuticals LLC | $198.93 | 2019-2023 | Contrave, Nexletol, Nexlizet |
| Esperion Therapeutics, INC. | $192.63 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $178.39 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.79 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $162.71 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $94.97 | 2019-2021 | |
| Angiodynamics, INC. | $86.53 | 2021 | |
| Abbott Laboratories | $72.32 | 2021-2023 | Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $71.31 | 2019-2025 | Seglentis, Zoryve |
| Phathom Pharmaceuticals, INC. | $67.03 | 2024-2025 | Voquezna |
| Allergan, INC. | $62.36 | 2019-2020 | |
| Vivus LLC | $61.07 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $60.93 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $60.27 | 2023-2024 | Rexulti, Nuedexta |
| Dexcom, INC. | $57.99 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $56.23 | 2022-2023 | Gvoke Hypopen |
| Insulet Corporation | $54.15 | 2024-2025 | Omnipod |
| Amgen INC. | $46.62 | 2019-2022 | |
| Amarin Pharma, INC. | $40.64 | 2019 | |
| Eisai INC. | $36.58 | 2021 | |
| Hologic Sales and Service, LLC | $30.77 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Indivior INC. | $30.24 | 2021-2025 | Sublocade |
| Pulmonx Corporation | $28.30 | 2021 | |
| Valeritas, INC. | $26.73 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.16 | 2025 | Caplyta |
| Almatica Pharma LLC | $17.37 | 2021 | |
| Lundbeck LLC | $17.14 | 2024 | Rexulti |
| Mannkind Corporation | $15.79 | 2019 | |
| Corium, LLC | $13.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dulan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.